• Explore /
  • Poster
  • / Preclinical assessment of IPH6501, a first-in-class IL2v-armed tetraspecific NK cell engager directed against CD20 for R/R B-NHL, in comparison with a CD20-targeting T cell engager.

Preclinical assessment of IPH6501, a first-in-class IL2v-armed tetraspecific NK cell engager directed against CD20 for R/R B-NHL, in comparison with a CD20-targeting T cell engager.

Abstract Poster

Authors

null

Olivier Demaria

Innate Pharma, Marseille, France

Olivier Demaria , Marie Vetizou , Romain Remark , Laura Chiossone , Constance Vagne , Rachel Courtois , Caroline Denis , Aurélie Maguer , François Le Floch , Agnès Represa , Audrey Blanchard Alvarez , Laurent Gauthier , Sonia Quaratino , Carine Paturel , Eric Vivier

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Cell Therapy, Bispecific Antibodies, and Autologous Stem Cell Transplantation for NHL, HL, or CLL

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 7030)

DOI

10.1200/JCO.2024.42.16_suppl.7030

Abstract #

7030

Poster Bd #

13

Abstract Disclosures

Similar Posters

First Author: Dagmar Hess

First Author: Ines Esteves Domingues Pires Da Silva

First Author: Joseph Gerald Pressey

Poster

2013 ASCO Annual Meeting

AFM11, a CD19/CD3 bispecific tandab, to facilitate T-cell-mediated killing of CD19+ cells.

AFM11, a CD19/CD3 bispecific tandab, to facilitate T-cell-mediated killing of CD19+ cells.

First Author: Eugene Zhukovsky